Keyphrases
Dominantly Inherited Alzheimer's Disease
100%
Solanezumab
100%
Gantenerumab
100%
Cognitive Decline
50%
Placebo
33%
Disease Progression
16%
Cerebrospinal Fluid
16%
Placebo Groups
16%
Mutation Carriers
16%
Total tau
16%
Randomized Placebo-controlled Trial
16%
Amyloid Plaques
16%
Beneficial Effects
16%
Phospho-tau181
16%
Edema
16%
Cause of Disease
16%
Imaging Biomarkers
16%
Clinical Symptoms
16%
Disease Stage
16%
Amyloid Imaging
16%
Fluid Biomarkers
16%
Mildly Symptomatic
16%
Neurofilament Light (NF-L)
16%
Cognitive Measures
16%
Target Dose
16%
Cognitive Imaging
16%
Biological Changes
16%
Single-arm Trial
16%
Clinical Biomarkers
16%
Cognitive Biomarkers
16%
Medicine and Dentistry
Alzheimer's Disease
100%
Gantenerumab
100%
Solanezumab
100%
Placebo
66%
Biological Marker
33%
Tau
16%
Cerebrospinal Fluid
16%
Arm
16%
Disease Exacerbation
16%
Amyloid Plaque
16%
Edema
16%
Neurofilament
16%
Light Chain
16%
Amyloid Protein
16%
Diseases
16%
Neuroscience
Alzheimer's Disease
100%
Gantenerumab
100%
Solanezumab
100%
Placebo
66%
Amyloid Protein
33%
Neurofilament Light Chain
16%
Biochemistry, Genetics and Molecular Biology
Gantenerumab
100%
Solanezumab
100%
Liquid
33%
Amyloid Protein
33%
Tau
16%
Light Chain
16%
Neurofilament Light
16%
Immunology and Microbiology
Solanezumab
100%
Gantenerumab
100%
Cerebrospinal Fluid
16%
Arm
16%
Liquid
16%
Light Chain
16%
Neurofilament
16%